|
PRPSAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.24720000005407E-06 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.462600E-01 |
| Stage1-vs-Stage3 |
7.202000E-02 |
| Stage1-vs-Stage4 |
3.395400E-04 |
| Stage2-vs-Stage3 |
2.677800E-02 |
| Stage2-vs-Stage4 |
3.198300E-04 |
| Stage3-vs-Stage4 |
4.193900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.576510E-04 |
| Normal-vs-Asian |
1.70263803056514E-12 |
| Caucasian-vs-AfricanAmerican |
3.891400E-01 |
| Caucasian-vs-Asian |
9.213800E-01 |
| AfricanAmerican-vs-Asian |
4.940800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
1.665640E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62747593179802E-12 |
| Normal-vs-Age(81-100Yrs) |
1.48030000002297E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.067800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.615000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.697800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.456000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.480600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.280200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.67687000000027E-05 |
| Classical-VS-Follicular |
1.062400E-03 |
| Classical-VS-Other |
8.505800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.63230001632076E-09 |
| Tall-VS-Other |
2.375700E-02 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.708600E-01 |
| Follicular-VS-Normal |
4.99470000003832E-06 |
| Other-VS-Normal |
2.606200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.16573417585641E-14 |
| Normal-vs-N1 |
1.77635683940025E-15 |
| N0-vs-N1 |
1.193290E-04 |
|
|
